Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 17.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 85,388 shares of the biopharmaceutical company’s stock after buying an additional 12,431 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Xenon Pharmaceuticals were worth $4,965,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in XENE. Cinctive Capital Management LP lifted its stake in Xenon Pharmaceuticals by 1.1% in the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock valued at $1,045,000 after buying an additional 263 shares during the last quarter. State of Wyoming increased its stake in shares of Xenon Pharmaceuticals by 30.4% during the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 350 shares during the period. Quarry LP increased its stake in shares of Xenon Pharmaceuticals by 25.0% during the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 500 shares during the period. Altfest L J & Co. Inc. raised its holdings in Xenon Pharmaceuticals by 6.5% during the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 501 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Xenon Pharmaceuticals by 11.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,574 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 675 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on XENE. Royal Bank Of Canada increased their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Guggenheim reissued a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Wedbush cut their target price on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, March 16th. Finally, Robert W. Baird raised their target price on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and an average price target of $77.20.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director directly owned 1,455 shares of the company’s stock, valued at $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gary Patou sold 1,322 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Price Performance

XENE opened at $60.96 on Monday. The company has a market capitalization of $5.89 billion, a PE ratio of -12.97 and a beta of 0.61. Xenon Pharmaceuticals Inc. has a fifty-two week low of $30.00 and a fifty-two week high of $63.95. The business has a 50-day moving average of $55.01 and a 200-day moving average of $50.31.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period last year, the company posted ($0.83) earnings per share. On average, equities research analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.